Mylan Ireland C/O Alloga Rdc, Pharmaceutical Import Profile — Netherlands (DGFT 2022–2026)

Name: Mylan Ireland C/O Alloga Rdc, Pharmaceutical Import Records from India — 5 Products, $11.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Mylan Ireland C/O Alloga Rdc, — Pharmaceutical Importer Profile (2026) | 5 Products, $11.0M Trade | TransData Nexus

Mylan Ireland C/O Alloga Rdc,

Pharmaceutical Importer · Netherlands · Cardiovascular Focus · $11.0M Total Trade · DGFT Verified

Mylan Ireland C/O Alloga Rdc, is a pharmaceutical importer based in Netherlands with a total trade value of $11.0M across 5 products in 4 therapeutic categories. Based on 302 verified import shipments from Indian Customs (DGFT) records, Mylan Ireland C/O Alloga Rdc, is the #1 buyer in 1 product including Rivaroxaban. Mylan Ireland C/O Alloga Rdc, sources from 1 verified Indian supplier, with Mylan Laboratories Limited accounting for 100.0% of imports.

Mylan Ireland C/O Alloga Rdc, — Import Portfolio & Supplier Network

Mylan Ireland C/O Alloga Rdc, import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Mylan Ireland C/O Alloga Rdc,?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Mylan Laboratories Limited	$26.6M	1,779	100.0%

Mylan Ireland C/O Alloga Rdc, sources from 1 verified Indian supplier across 1,099 distinct formulations. The sourcing is highly concentrated — Mylan Laboratories Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Harmless medicines, sitagliptin mylan	$451.9K	14
Harmless medicines, candesartan	$387.9K	13
Harmless medicines, darunavir mylan	$323.4K	9
Harmless medicines, esomeprazol mylan	$300.2K	9
Harmless medicines, kandrozid 16 MG	$276.9K	7
Harmless medicines, esomeprazol mylan	$264.8K	9
Harmless medicines, lansoprazole 30MG	$262.3K	7
Pregabalin mylan 150 MG 56 bl cap	$252.0K	7
Sitagliptin mylan 100 MG 28 bl TAB	$213.6K	10
Harmless medicines, lopinavir /	$200.0K	4
Harmless medicines, sitagliptina mylan	$189.4K	4
Harmless medicines, rosuvastatina	$182.2K	5
Harmless medicines, eletriptan quiver	$169.6K	6
Harmless medicines, cinacalcet mylan	$166.4K	5
Harmless medicines, esomeprazole	$150.0K	3

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Rivaroxaban	Cardiovascular	$5.1M	129	7.9%	1
2	Lansoprazole	Gastrointestinal	$3.2M	81	1.1%	6
3	Sitagliptin	Diabetes & Endocrine	$1.6M	57	2.1%	11
4	Darunavir	Antiviral & HIV Medications	$999.6K	33	1.7%	7
5	Lisinopril	Cardiovascular	$100.0K	2	0.2%	3

Mylan Ireland C/O Alloga Rdc, imports 5 pharmaceutical products across 4 categories into Netherlands totaling $11.0M. The company is the #1 buyer for 1 product: Rivaroxaban.

Mylan Ireland C/O Alloga Rdc, — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Mylan Ireland C/O Alloga RDC is a pharmaceutical importer and buyer based in the Netherlands, specializing in the acquisition of finished pharmaceutical formulations from India. Operating as a subsidiary of Mylan Laboratories Limited, the company plays a pivotal role in the distribution of generic and specialty pharmaceuticals within the Dutch market. Mylan Laboratories Limited, headquartered in Hatfield, Hertfordshire, UK, is a global leader in the production of generic and specialty medicines. The Netherlands serves as a strategic hub for Mylan's European operations, facilitating the efficient distribution of pharmaceutical products across the continent.

2Distribution Network

Mylan Ireland C/O Alloga RDC's distribution network is centered in the Netherlands, with facilities located in Wijchen, a city in the province of Gelderland. The company's logistics capabilities are designed to ensure the timely and efficient delivery of pharmaceutical products throughout the Netherlands and into neighboring European markets. By leveraging the Netherlands' well-developed infrastructure and strategic location, Mylan Ireland C/O Alloga RDC effectively manages its supply chain operations to meet the demands of the European pharmaceutical sector.

3Industry Role

In the Netherlands' pharmaceutical supply chain, Mylan Ireland C/O Alloga RDC functions primarily as a pharmaceutical importer and buyer. By sourcing finished pharmaceutical formulations from India, the company acts as a conduit between Indian manufacturers and the Dutch market, facilitating the availability of generic and specialty medicines. This role is crucial in ensuring that a diverse range of affordable and high-quality pharmaceutical products are accessible to healthcare providers and patients in the Netherlands.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Mylan Ireland C/O Alloga Rdc,

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Mylan Ireland C/O Alloga RDC demonstrates a high level of sourcing concentration, importing finished pharmaceutical formulations exclusively from Mylan Laboratories Limited in India. This single-source dependency indicates a strategic choice to maintain consistency in product quality and supply chain efficiency. The substantial volume of imports—302 shipments totaling $11.0 million USD—suggests a stable and robust relationship between Mylan Ireland C/O Alloga RDC and Mylan Laboratories Limited. However, this concentration also exposes the company to potential risks associated with supply chain disruptions or changes in the supplier's operational status.

2Supply Chain Resilience

The resilience of Mylan Ireland C/O Alloga RDC's supply chain is closely tied to its exclusive reliance on Mylan Laboratories Limited for sourcing finished pharmaceutical formulations. While this arrangement ensures uniformity in product quality, it also means that the company lacks alternative suppliers to mitigate potential disruptions. The diversity of imported formulations—1099 unique products across various therapeutic categories—indicates a broad product portfolio, which can help buffer against market fluctuations. Nonetheless, the absence of backup suppliers and the concentration of shipments through specific routes may pose challenges in maintaining supply chain continuity during unforeseen events.

Importing Pharmaceuticals into Netherlands — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Netherlands

1Regulatory Authority & Framework

In the Netherlands, the primary regulatory authority overseeing pharmaceutical imports is the Dutch Medicines Evaluation Board (CBG-MEB), which operates under the Ministry of Health, Welfare, and Sport. The CBG-MEB is responsible for evaluating and monitoring the safety, efficacy, and quality of medicines available in the Dutch market. Key legislation governing pharmaceutical imports includes the Medicines Act (Geneesmiddelenwet), which outlines the requirements for marketing authorization, and the Dutch Medicines Regulation (Regeling Geneesmiddelenwet), which provides detailed provisions on the importation and distribution of medicinal products. For Indian generics to enter the Dutch market, they must undergo a centralized marketing authorization procedure through the European Medicines Agency (EMA), ensuring compliance with EU standards.

2Import Licensing & GMP

Import licensing requirements in the Netherlands stipulate that pharmaceutical importers must hold a valid wholesale distribution authorization issued by the CBG-MEB. This authorization ensures that importers adhere to Good Distribution Practice (GDP) guidelines, maintaining the integrity of medicinal products throughout the supply chain. Regarding Good Manufacturing Practice (GMP), the Netherlands recognizes certifications from the European Union (EU GMP), World Health Organization (WHO GMP), and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Indian exporters seeking to supply Mylan Ireland C/O Alloga RDC must ensure that their manufacturing facilities are certified by one of these recognized bodies to meet the quality standards required for the Dutch market.

Mylan Ireland C/O Alloga Rdc, — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Mylan Ireland C/O Alloga RDC's product category focus—Cardiovascular (46.9%), Gastrointestinal (29.2%), and Diabetes & Endocrine (14.7%)—aligns with prevalent health concerns in the Netherlands. The substantial import value of Rivaroxaban ($5.1 million) indicates a strong demand for cardiovascular treatments. The inclusion of Lansoprazole and Sitagliptin reflects the company's commitment to addressing gastrointestinal and diabetic conditions, respectively. This strategic product selection is driven by the high incidence of these diseases in the Dutch population, necessitating a steady supply of effective and affordable medications.

2Sourcing Profile

Mylan Ireland C/O Alloga RDC's sourcing strategy is centered on importing generic drug formulations from Mylan Laboratories Limited in India. The company's preference for finished pharmaceutical formulations over active pharmaceutical ingredients (APIs) suggests a focus on ready-to-market products that can be swiftly distributed within the Netherlands. India's robust pharmaceutical manufacturing sector, known for its compliance with international quality standards, makes it a strategic partner for Mylan Ireland C/O Alloga RDC in fulfilling the Dutch market's pharmaceutical needs.

3Market Positioning

Seller's Guide — How to Become a Supplier to Mylan Ireland C/O Alloga Rdc,

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

For new Indian suppliers, entering the Dutch market through Mylan Ireland C/O Alloga RDC presents challenges due to the existing exclusive sourcing arrangement. However, opportunities may exist in therapeutic areas not currently covered by the existing portfolio, where new suppliers can introduce innovative products to meet unmet market needs. Additionally, offering competitive pricing, ensuring compliance with EU GMP standards, and demonstrating a commitment to quality can enhance the attractiveness of new suppliers to Mylan Ireland C/O Alloga RDC.

2Requirements & Qualifications

Indian exporters seeking to supply Mylan Ireland C/O Alloga RDC and the broader Netherlands market must obtain certifications from recognized bodies such as EU GMP, WHO GMP, or PIC/S. Compliance with Dutch labeling requirements, including Dutch language labeling, batch testing, stability, and serialization mandates, is essential. Additionally, adherence to the Medicines Act and the Dutch Medicines Regulation is required to ensure that products meet the safety, efficacy, and quality standards set by the CBG-MEB.

3How to Approach

Frequently Asked Questions — Mylan Ireland C/O Alloga Rdc,

What products does Mylan Ireland C/O Alloga Rdc, import from India?

Mylan Ireland C/O Alloga Rdc, imports 5 pharmaceutical products across 4 categories. Top imports: Rivaroxaban ($5.1M), Lansoprazole ($3.2M), Sitagliptin ($1.6M), Darunavir ($999.6K), Lisinopril ($100.0K).

Who supplies pharmaceuticals to Mylan Ireland C/O Alloga Rdc, from India?

Mylan Ireland C/O Alloga Rdc, sources from 1 verified Indian suppliers. The primary supplier is Mylan Laboratories Limited (100.0% of imports, $26.6M).

What is Mylan Ireland C/O Alloga Rdc,'s total pharmaceutical import value?

Mylan Ireland C/O Alloga Rdc,'s total pharmaceutical import value from India is $11.0M, based on 302 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Mylan Ireland C/O Alloga Rdc, focus on?

Mylan Ireland C/O Alloga Rdc, imports across 4 categories. The largest: Cardiovascular (46.9%), Gastrointestinal (29.2%), Diabetes & Endocrine (14.7%).

Get Full Mylan Ireland C/O Alloga Rdc, Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.